Cargando…

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US

BACKGROUND: Treatment with venetoclax + hypomethylating agents (HMAs) is standard-of-care for newly diagnosed (ND) patients with acute myeloid leukemia (AML) aged ≥75 years, or with comorbidities precluding intensive chemotherapy. We describe real-world venetoclax + HMA treatment practices and outco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vachhani, Pankit, Flahavan, Evelyn M, Xu, Tao, Ma, Esprit, Montez, Melissa, Gershon, Anda, Onishi, Maika, Jin, Huan, Ku, Grace, Flores, Brannon, Bui, Cat N, Abbas, Jonathan A, Donnellan, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Academia-Pharma Intersect
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632323/ https://www.ncbi.nlm.nih.gov/pubmed/35925602 http://dx.doi.org/10.1093/oncolo/oyac135

Ejemplares similares

Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
por: Ludwig, Heinz, et al.
Publicado: (2010)

Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer
por: Thatcher, Nicholas, et al.
Publicado: (2010)

Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New Agents
por: Moxley, Katherine M., et al.
Publicado: (2010)

Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases
por: Aapro, Matti, et al.
Publicado: (2010)

Fatigue in Renal Cell Carcinoma: The Hidden Burden of Current Targeted Therapies
por: Larkin, James M.G., et al.
Publicado: (2010)

Lapatinib plus Letrozole as First-Line Therapy for HER-2(+) Hormone Receptor–Positive Metastatic Breast Cancer
por: Schwartzberg, Lee S., et al.
Publicado: (2010)

Targeting Signal Transduction Pathways in Metastatic Breast Cancer: A Comprehensive Review
por: Rosen, Lee S., et al.
Publicado: (2010)

Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review
por: Agarwala, Sanjiv S., et al.
Publicado: (2010)

Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery
por: Tejpar, Sabine, et al.
Publicado: (2010)

Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer
por: Scagliotti, Giorgio, et al.
Publicado: (2010)

Effect of Patient Age on Management Decisions in Breast Cancer: Consensus from a National Consultation
por: Leonard, Robert C., et al.
Publicado: (2010)

Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study
por: Extra, Jean-Marc, et al.
Publicado: (2010)

Quality of Life in Hormone Receptor–Positive HER-2(+) Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib
por: Sherrill, Beth, et al.
Publicado: (2010)

Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
por: Cameron, David, et al.
Publicado: (2010)

Epoetin Alfa Improves Anemia and Anemia-Related, Patient-Reported Outcomes in Patients with Breast Cancer Receiving Myelotoxic Chemotherapy: Results of a European, Multicenter, Randomized, Controlled Trial
por: Pronzato, Paolo, et al.
Publicado: (2010)

Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
por: Garbe, Claus, et al.
Publicado: (2011)

The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab
por: Castellano, Daniel, et al.
Publicado: (2011)

Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment
por: Aggarwal, Rahul, et al.
Publicado: (2011)

Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
por: Popat, Sanjay, et al.
Publicado: (2022)

Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?
por: Boccia, Ralph, et al.
Publicado: (2022)

Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib
por: Wander, Seth A, et al.
Publicado: (2022)

Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction
por: Wang, Tzu-Fei, et al.
Publicado: (2023)

Post‐remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre‐ versus post‐VIALE‐A real‐world experience from a predominantly US community setting
por: Vachhani, Pankit, et al.
Publicado: (2023)

Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents
por: Cheson, Bruce D., et al.
Publicado: (2017)

Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy
por: Baik, Christina S., et al.
Publicado: (2017)

Hormone Receptor–Positive/Human Epidermal Growth Receptor 2–Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents
por: Shah, Ami N., et al.
Publicado: (2020)

Intratumoral Immunotherapy—Update 2019
por: Hamid, Omid, et al.
Publicado: (2019)

What is linking COVID-19 and endothelial dysfunction? Updates on nanomedicine and bioengineering from the 2020 AHA Scientific Sessions
por: Gambardella, Jessica, et al.
Publicado: (2020)

News
Publicado: (2023)

AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax
por: Low, Soon Khai, et al.
Publicado: (2022)

Female excellence in rock climbing likely has an evolutionary origin
por: Carroll, Collin
Publicado: (2021)

High-fat diet-associated cognitive decline: Is zinc finger protein 1 (ZPR1) the molecular connection?
por: Chittilla, Mythri, et al.
Publicado: (2021)

Getting everyone to the table: exploring everyday and everynight work to consider ‘latent social threats’ through interprofessional tabletop simulation
por: Brydges, Ryan, et al.
Publicado: (2021)

Laughter therapy: A humor-induced hormonal intervention to reduce stress and anxiety
por: Akimbekov, Nuraly S., et al.
Publicado: (2021)

Critical design choices in healthcare simulation education: a 4C/ID perspective on design that leads to transfer
por: Frerejean, Jimmy, et al.
Publicado: (2023)

Data-driven resuscitation training using pose estimation
por: Weiss, Kerrin E., et al.
Publicado: (2023)

Measuring cognitively demanding activities in pediatric out-of-hospital cardiac arrest
por: Bahr, Nathan, et al.
Publicado: (2023)

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM
por: Huemer, Florian, et al.
Publicado: (2019)

Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax
por: Candoni, Anna, et al.
Publicado: (2022)

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
por: Hammond, Danielle, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0hnrivpgbo93cpfgmu6dtmlof9